摘要
该文详述了卵巢癌中病人来源的类器官(patient-derived organoids,PDOs)模型的构建及培养方式,以证实该实验方式具有可重复性与较高的性价比。分析药物筛选结果与临床药物反应性,旨在证明该模型对临床治疗的价值。同时,为扩展类器官模型的应用范围,采用了DNA损伤相关的彗星实验、DNA fiber实验以及免疫荧光、蛋白电泳等实验技术,探索以该模型为基础的各项实验技术的可行性。结果表明,PDOs模型中的药物筛选结果可以模拟临床病人对药物的反应性,铂类化疗治疗效果与PDOs模型中的药物敏感性具有显著相关性。除常规使用的化疗药物以外,也可以通过该模型的药物筛选摸索病人治疗的最佳用药方式,并推动未进入临床的新药的研发。
This study aims to introduce a cost-effectiveness way to establish and culture a PDOs (patient-derived organoids) model of high grade serous ovarian cancer in detail.The results reveal the clinical value of PDOs model in choosing drugs for chemotherapy.To further extend the application of this model,techniques including comet assay,DNA fiber,immunofluorescence and Western blot are also successfully applied in PDOs models.By comparing the results of drug screening and clinical outcome after platinum treatment,a significant correlation of organoids and primary tumor tissue in drug sensitivity is found.In this article,PDOs model is verified to be necessary for exploring the best way to treat patients and promote the development of new drugs.
作者
黄雨涵
刘陈
秦天予
孙朝阳
陈刚
HUANG Yuhan;LIU Chen;QIN Tianyu;SUN Chaoyang;CHEN Gang(Department of Obstetrics and Gynecology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)
出处
《中国细胞生物学学报》
CAS
CSCD
2021年第6期1174-1183,共10页
Chinese Journal of Cell Biology
基金
国家自然科学基金(批准号:81974408)资助的课题。
关键词
卵巢癌
类器官模型
药物筛选
ovarian cancer
patient-derived-organoids model
drug screening
